Getinge reported mixed Q4 numbers. Q4 sales were up 2.4% to SEK7.9bn, ahead of our conservative estimates, but missing the street’s consensus. The order book came in at SEK6.7bn, contracting by 3.1%. NB all growth numbers are on an organic basis, unless mentioned otherwise. Segment-wise, the life sciences segment was the clear outperformer (+15.5% vs -9.8% in Q3 18, +32.7% in Q2 18, -2.5% in Q1 18), making up for a muted performance from the acute care therapies (ACT) segment (+0.3% vs
31 Jan 2019
The market cheers mixed Q4 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The market cheers mixed Q4 results
Getinge AB Class B (GTN:FRA) | 0 0 0.9% | Mkt Cap: 25,911m
- Published:
31 Jan 2019 -
Author:
Kamla Singh -
Pages:
3
Getinge reported mixed Q4 numbers. Q4 sales were up 2.4% to SEK7.9bn, ahead of our conservative estimates, but missing the street’s consensus. The order book came in at SEK6.7bn, contracting by 3.1%. NB all growth numbers are on an organic basis, unless mentioned otherwise. Segment-wise, the life sciences segment was the clear outperformer (+15.5% vs -9.8% in Q3 18, +32.7% in Q2 18, -2.5% in Q1 18), making up for a muted performance from the acute care therapies (ACT) segment (+0.3% vs